Marie Bosslett, Assistant Editor

The product was safe and effective after 4 weeks of topical use, specifically on patients with darker skin types.

A new case report demonstrated the JAK inhibitor’s efficacy at improving disease severity up to 6 months.

The method was safe and effective with high patient satisfaction rates 4 weeks post-injection.

In case you missed it, this week we had news about pregnancy-related skin changes, art in clinical spaces, Allergan's upcoming skin quality index, and more.

Allergan’s latest initiative hopes to empower both patients and clinicians while advancing industry standards, according to Sherket Peterson, PhD.

Sherket Peterson, PhD, spoke to Dermatology Times about Allergan’s recent research and plan to launch a universal skin quality index.

Jiyeon Oh’s research confirms that a personalized approach is needed to treat all complexities associated with AD.

Researcher Jiyeon Oh shares results of a recent study that confirm the prevalence of AD is stable, but disease burden is rising.

Positive changes in DLQI scores were observed after 4 weeks of therapy as well as the 6-month follow-up.

Misinformation from outside sources creates unrealistic expectations for pregnancy and postpartum skin conditions like hyperpigmentation.

2% and 4% formulations of the product were effective and tolerable for patients with varying scalp conditions.

Nearly all patients saw improvements in small, medium, and large depressions on the cheeks and temples with just a singular treatment session.

Compared to patients with rheumatoid arthritis and atopic dermatitis, those with vitiligo had a lower incidence of major adverse effects.

This month and all year round, we recognize the strides and contributions of female leaders in dermatology.

In case you missed it, this week we had news about CBD products in dermatology, Journey Medical's launch of Emrosi for rosacea, the psychological impact of melanoma, and more.

Patients with CHE saw higher treatment success and a favorable safety profile with delgocitinib 20-30 mg/g.

Two-sample Mendelian randomization analysis explored lifestyle factors such as sleep, smoking, alcohol consumption, and sedentary behavior.

The therapy, which combines clindamycin phosphate, adapalene, and benzoyl peroxide, was effective for Hispanic patients with moderate to severe lesions.

In a prospective study, patients with scalp seborrheic dermatitis saw positive results in efficacy, safety, and quality of life when using the AgNP product.

Treatment with tildrakizumab was still safe and effective after 1 year with notable improvements in patients’ quality of life.

Use of the product showed positive changes in the skin’s hydration, lipid content, transepidermal water loss, and erythema.

When compared to a non-active product, the formula improved texture, reduced erythema, and strengthened the skin barrier.

The novel treatments will be for patients with orphan conditions like Netherton Syndrome, Peeling Skin Syndrome, SAM Syndrome, and palmoplantar keratoderma.

Each treatment had benefits and disadvantages for patients who struggle with rosacea-associated erythema.

Participants from the parent DELTA 1 and 2 studies maintained their disease control and observed a decrease in pain and itch over 52 weeks of treatment.

As a featured clinician in EltaMD’s Derm Day campaign, Mona Gohara, MD, spoke about her connection with the brand and the work being done to unify dermatologists and promote skin health.

In case you missed it, this week we had news about positive results from Incyte’s phase 3 STOP-HS trials, multidisciplinary approaches to advanced BCC and CSCC, pediatric ocular adverse effects associated with dupilumab, and more.

Eve Arnera and Thandiwe Munaiwa, MD, spoke about the groundbreaking collaboration between SkinCeuticals and ReSurge International, “Pioneering Women in Reconstructive Surgery.”

The 730-nm picosecond laser had an efficacy rate of 88% with higher patient satisfaction compared to the 1604-nm wavelength.

This real-world data explores the use of the IL-17A blocker for up to 3 years in several subtypes of psoriasis.